I will deliver drug pricing, reimbursement, and market access reports

Pricing and reimbursement decisions can make or break a drug's commercial success, and every major market evaluates value differently. I help pharma and biotech teams analyze how a product will be assessed, priced, and reimbursed across key global markets, using official HTA (Health Technology Assessment) documents.

Key markets that we cover:

North America

• ICER (US) cost-effectiveness and value assessment
• CDA (Canada) Canadian Drug Agency reimbursement reviews

Europe

• NICE (UK) technology appraisals
• HAS (France) Transparency Committee, SMR/ASMR ratings
• G-BA / IQWiG (Germany) early benefit assessment (AMNOG)
• AEMPS (Spain) IPT Documents
• AIFA (Italy) Class and reimbursement population
• ZIN (Netherlands)
• TLV (Sweden)
• SMC (Scotland)
• KCE (Belgium)
• NCPE (Ireland)

Asia-Pacific

• PBAC (Australia) Pharmaceutical Benefits Advisory Committee
• MHLW / Chuikyo (Japan) drug pricing and premiums
• NHSA (China) NDRL List analysis

Latin America

• CONITEC (Brazil) HTA recommendations for the public health system

What you get: Well-researched content in either presentation/pdf/word/excel